Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
What to make of Gilead's latest NASH deal
Biopharma Dive
Mon, 10/28/19 - 11:04 pm
Gilead Sciences
Glympse Bio
biomarkers
NASH
Novartis bets $80M on Pliant's preclinical NASH prospect
Fierce Biotech
Wed, 10/23/19 - 10:39 pm
Novartis
NASH
Pliant Therapeutics
PLN-1474
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Motley Fool
Wed, 10/23/19 - 10:40 am
liver disease
NASH
The Liver Meeting
Assembly Biosciences
CymaBay Therapeutics
Madrigal Pharmaceuticals
Early readout from small NGM study shows NASH drug hits liver fat, but shares fall
Fierce Biotech
Mon, 10/7/19 - 11:05 am
NGM Biopharmaceuticals
NASH
clinical trials
FGF19 aldafermin
Enanta's NASH drug barely meets main goal in mid-stage study
Endpoints
Thu, 09/26/19 - 10:59 am
Enanta
NASH
clinical trials
EDP-305
Genfit’s liver disease Hail Mary approaches
EP Vantage
Thu, 09/19/19 - 08:10 pm
Genfit
NASH
elafibranor
89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team
CP WIre
Fri, 08/9/19 - 08:11 pm
89Bio
NASH
NAFLD
clinical trials
89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team
Fri, 08/9/19 - 08:10 pm
89Bio
NASH
NAFLD
clinical trials
NASH-linked gene discovery could inspire new drugs to treat liver damage
Fierce Biotech
Fri, 07/19/19 - 12:50 pm
NASH
R&D
drug development
genetics
liver damage
liver fibrosis
Faced with a PhIII flop in NASH, Gilead is sequencing 15,000 patients to find new drugs
Endpoints
Thu, 07/11/19 - 10:35 am
Gilead Sciences
NASH
Renown Institute
gene sequencing
Boehringer races to catch up in NASH through Yuhan deal
BioCentury
Mon, 07/1/19 - 10:47 pm
Boehringer Ingelheim
NASH
Yuhan
Conatus to Slash Staff, Consider Sale After NASH Trial Failures
Xconomy
Tue, 06/25/19 - 09:13 am
Conatus Pharmaceuticals
NASH
layoffs
emricasan
Conatus Pharma to explore options as liver disease drug fails trial
Yahoo/Reuters
Mon, 06/24/19 - 07:20 pm
Conatus Pharmaceuticals
clinical trials
NASH
emricasan
Novartis
CymaBay Therapeutics Stumbles in NASH Race, Shares Fall
Xconomy
Tue, 06/11/19 - 10:11 am
CymaBay
NASH
clinical trials
seladelpar
NASH drugmaker stocks rebound after dip on FDA guidance
Biopharma Dive
Mon, 06/10/19 - 06:08 pm
NASH
FDA
Madrigal Pharmaceuticals
Viking Therapeutics
Intercept Pharma
Genfit
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Fierce Biotech
Mon, 06/10/19 - 09:39 am
Eli Lilly
NASH
tirzepatide
clinial trials
ADA
type 2 diabetes
No one knows the size of the NASH market
Biopharma Dive
Thu, 05/16/19 - 06:52 pm
NASH
NIH
Will a big needle burst the NASH bubble?
Biopharma Dive
Tue, 05/14/19 - 11:41 pm
diagnostics
liver disease
NASH
liver biopsies
Promethera raises €40M to fund trial of NASH cell therapy
Fierce Biotech
Mon, 05/6/19 - 09:50 pm
Promethera Biosciences
NASH
2 Reasons Gilead Sciences' NASH Program Could Bounce Back
Motley Fool
Sun, 04/28/19 - 12:20 pm
Gilead Sciences
NASH
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »